vs

Side-by-side financial comparison of Paranovus Entertainment Technology Ltd. (PAVS) and Verastem, Inc. (VSTM). Click either name above to swap in a different company.

Paranovus Entertainment Technology Ltd. is the larger business by last-quarter revenue ($12.4M vs $11.2M, roughly 1.1× Verastem, Inc.). Paranovus Entertainment Technology Ltd. runs the higher net margin — -5.5% vs -876.3%, a 870.9% gap on every dollar of revenue.

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

PAVS vs VSTM — Head-to-Head

Bigger by revenue
PAVS
PAVS
1.1× larger
PAVS
$12.4M
$11.2M
VSTM
Higher net margin
PAVS
PAVS
870.9% more per $
PAVS
-5.5%
-876.3%
VSTM

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
PAVS
PAVS
VSTM
VSTM
Revenue
$12.4M
$11.2M
Net Profit
$-681.0K
$-98.5M
Gross Margin
20.0%
Operating Margin
-5.1%
-362.2%
Net Margin
-5.5%
-876.3%
Revenue YoY
18033.4%
Net Profit YoY
61.4%
-311.1%
EPS (diluted)
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PAVS
PAVS
VSTM
VSTM
Q3 25
$12.4M
$11.2M
Q2 25
$2.1M
Q3 24
$0
Q2 24
$10.0M
Q3 23
$0
Net Profit
PAVS
PAVS
VSTM
VSTM
Q3 25
$-681.0K
$-98.5M
Q2 25
$-25.9M
Q3 24
$-24.0M
Q2 24
$-8.3M
Q3 23
$8.2M
Gross Margin
PAVS
PAVS
VSTM
VSTM
Q3 25
20.0%
Q2 25
Q3 24
Q2 24
Q3 23
Operating Margin
PAVS
PAVS
VSTM
VSTM
Q3 25
-5.1%
-362.2%
Q2 25
-2047.9%
Q3 24
Q2 24
-182.8%
Q3 23
Net Margin
PAVS
PAVS
VSTM
VSTM
Q3 25
-5.5%
-876.3%
Q2 25
-1213.6%
Q3 24
Q2 24
-82.6%
Q3 23
EPS (diluted)
PAVS
PAVS
VSTM
VSTM
Q3 25
$-1.35
Q2 25
$-0.62
Q3 24
$-0.60
Q2 24
$-0.31
Q3 23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PAVS
PAVS
VSTM
VSTM
Cash + ST InvestmentsLiquidity on hand
$5.2M
$137.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$23.6M
$-15.5M
Total Assets
$37.3M
$176.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PAVS
PAVS
VSTM
VSTM
Q3 25
$5.2M
$137.7M
Q2 25
$164.3M
Q3 24
$113.2M
Q2 24
$83.4M
Q3 23
$1.0M
Total Debt
PAVS
PAVS
VSTM
VSTM
Q3 25
Q2 25
Q3 24
$40.5M
Q2 24
$40.3M
Q3 23
Stockholders' Equity
PAVS
PAVS
VSTM
VSTM
Q3 25
$23.6M
$-15.5M
Q2 25
$36.1M
Q3 24
$11.1M
Q2 24
$18.9M
Q3 23
$10.7M
Total Assets
PAVS
PAVS
VSTM
VSTM
Q3 25
$37.3M
$176.9M
Q2 25
$196.3M
Q3 24
$126.4M
Q2 24
$105.7M
Q3 23
$11.2M
Debt / Equity
PAVS
PAVS
VSTM
VSTM
Q3 25
Q2 25
Q3 24
3.66×
Q2 24
2.14×
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PAVS
PAVS
VSTM
VSTM
Operating Cash FlowLast quarter
$-159.3K
$-36.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PAVS
PAVS
VSTM
VSTM
Q3 25
$-159.3K
$-36.2M
Q2 25
$-32.7M
Q3 24
$-23.8M
Q2 24
$-27.6M
Q3 23
$-13.1M
Free Cash Flow
PAVS
PAVS
VSTM
VSTM
Q3 25
Q2 25
Q3 24
Q2 24
$-27.6M
Q3 23
FCF Margin
PAVS
PAVS
VSTM
VSTM
Q3 25
Q2 25
Q3 24
Q2 24
-275.8%
Q3 23
Capex Intensity
PAVS
PAVS
VSTM
VSTM
Q3 25
Q2 25
Q3 24
Q2 24
0.1%
Q3 23
Cash Conversion
PAVS
PAVS
VSTM
VSTM
Q3 25
Q2 25
Q3 24
Q2 24
Q3 23
-1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons